Company intelligence / Profile preview
TATUM Bioscience
Sherbrooke, Quebec, Canadatatumbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TATUM Bioscience is developing a proprietary synthetic biology platform to create multimodal nanofilaments—synthetic advanced biologics—that stimulate comprehensive antitumor immune responses. Their approach aims to combine the benefits of combination immunotherapy into a single agent, potentially offering safer and more effective cancer treatments. The company remains in preclinical development with no reported clinical trial outcomes yet.
- Therapeutic areas
- Oncology
- Modalities
- Nanofilament-based therapySynthetic advanced biologics (synABs)Biologic (general category)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
adMare BioInnovations Tx AcceleratorSCbioDrive Accelerator Program
Beyond the preview
Go deeper on TATUM Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TATUM Bioscience.